Coffee Consumption and Metabolic Health

Background: Coffee is among the most widely consumed beverages globally, and its relationship with metabolic health has been the subject of extensive but sometimes contradictory research. While early epidemiological concerns about cancer risk have largely been resolved, the specific mechanisms through which coffee's bioactive compounds influence metabolic outcomes remain incompletely understood, particularly when accounting for variation in roasting profiles and preparation methods. Methods: This review synthesizes evidence from observational studies, randomized controlled trials, and mechanistic investigations published between 1991 and 2026 to examine how coffee consumption affects metabolic health, with attention to cardiovascular protection, type 2 diabetes risk reduction, glucose and lipid metabolism, hepatic health and bone health. Results: Moderate coffee consumption, approximately three to four standard cups per day, is consistently associated with favorable cardiometabolic outcomes, particularly when coffee is filtered. Paper filtration retains many phenolic compounds while substantially reducing diterpenes, whereas unfiltered preparations deliver higher cafestol and kahweol exposure and can elevate LDL cholesterol. Roast level further alters chlorogenic acid, melanoidin, and trigonelline concentrations, with medium roasts retaining a more favorable balance of chlorogenic acids and trigonelline than darker roasts, although human outcome data comparing roast levels remain limited. Conclusion: Evidence supports a protective association between moderate coffee intake and metabolic health, but the magnitude and direction of effects depend on roast type, brewing method, and caffeine-metabolism phenotype. Because clinical trials rarely control for roast profile and brewing method together, future research should use standardized coffee preparations before dietary guidance can move beyond generic cup-per-day recommendations.